$BSX

17 ETFs Add to Boston Scientific (BSX) on Oct. 21

On October 21, 17 ETFs added shares of Boston Scientific (BSX) totaling $23.9 million, extending a three-day streak of net inflows. The largest buyers were CGGO, IHI, and SPYM. BSX operates in the medical devices sector with a market cap of $66.7 billion. ETFs have been net buyers of BSX in 3 of the last 5 days.

Original reporting
Published Oct 23, 2026, 11:02 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
17 ETFs Add to Boston Scientific (BSX) on Oct. 21 — source image
Decision brief

The 30-second read

$BSXNeutralLow
01

Why it matters

ETF inflows suggest short‑term buying interest but lack a substantive catalyst for larger price moves.

02

Market read

ETF activity provides a modest, short‑term signal for BSX but does not constitute major news.

03

What to watch

No new corporate news; flows may reflect portfolio rebalancing rather than fundamental catalyst.

Relevance 4/10Novelty 4/10Timing: today

Background

Boston Scientific (BSX) is a $66.7 B medical‑device maker. The article reports recent ETF flow data.

Company-level read

Ticker impact

$BSXNeutralMedium confidence
Context

ETFs added a net $23.9 M of Boston Scientific shares on Oct 21, extending a three‑day buying streak.

Expected impact

potential modest upside as ETFs increase holdings

Evidence & confidence

ETF net buying of $23.9 M is a fresh flow signal but limited in scale for a $66.7 B market‑cap.

Market effects

Shows continued investor interest in medical‑device sector via ETF allocations.

US market may see slight uplift in healthcare‑related ETFs.

Limited to US equity investors; no broader macro impact.

Counterpoint

ETF buying could be temporary and may reverse if broader market sentiment shifts.

Key entities

  • Boston Scientific

    Medical‑device manufacturer, ticker BSX.

Related articles

$BSXHigh

Stifel cuts Boston Scientific stock price target on cyberattack impact

Stifel reduced its price target for Boston Scientific (BSX) to $55 from $60, citing the impact of a cyberattack. The company expects material effects on Q3 2026 and full-year 2026 results, leading to lower revenue projections and revised earnings estimates. Analysts remain divided, with some maintaining buy ratings and others lowering targets due to competitive pressures.

$PENHighAI 9/10

Deep Vein Thrombosis (DVT)

Penumbra, Inc. received FDA clearance for its Lightning device to treat deep vein thrombosis. Boston Scientific Corp. agreed to acquire Penumbra in a cash and stock deal. Penumbra's stock may be affected by the acquisition and new product approval.

$BSXMed

Boston sues J&J subsidiary over alleged patent infringement for cardiology device

Boston Scientific sued Johnson & Johnson subsidiary Atraverse Medical, alleging patent infringement by its Hotwire device. Boston claims Atraverse knew its actions infringed Patent '955 and seeks damages and an injunction. J&J acquired Atraverse in 2026. The electrophysiology ablation catheter market is growing at 11.1% CAGR, with J&J's Biosense Webster leading at 43.1% market share in 2025.

$BSXMed

Boston Scientific (BSX) Names Joseph Fitzgerald COO, Restructure

Boston Scientific (BSX) appointed Joseph M. Fitzgerald as COO, effective January 1, 2027, and restructured operations into three segments. The company is valued at $42.19, with a GF Value™ of $107.35, indicating a 60.7% undervaluation. BSX has a GF Score™ of 79, reflecting strong financial health and growth prospects, despite net insider selling and mixed guru activity.